RBC Capital Downgrades Design Therapeutics Inc (DSGN) to Sector Perform 'pending further derisking'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
August 14, 2023 4:05 PM EDTInitial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels in Skeletal Muscle
Company Expects to Resume a Multiple Dose Phase 1 Clinical Study with DT-216 with an Improved Formulation in the Second Half of 2024 and Report Data in the First Half of 2025
IND Submission for FECD GeneTAC Program On-track for the Second Half of 2023
$303.1 Million in Cash and Securities Expected to Support Operating Runway through 2026
CARLSBAD, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq:... More
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
August 14, 2023 4:01 PM EDTDT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients
Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation Composition
Design Plans to Proceed with an Improved DT-216 Formulation and Initiate a Multiple Dose Phase 1 Clinical Study in the Second Half of 2024
Conference Call and Webcast to be Held Today at 4:30pm ET
CARLSBAD, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing... More
